股份回購 此公告乃藥師幫股份有限公司（「本公司」）自願向本公司股東（「股 東」）及本公司 潛 在 投 資 者 作 出。 茲提述本公司日期為2025年5月7日、2025年5月9日、2025年5月12日、2025年5月 13日、2025年5月14日、2025年5月15日、2025年5月16日、2025年5月19日、2025年5 月21日、2025年5月22日、2025年5月23日、2025年5月26日、2025年5月27日、2025 年6月4日、2025年6月5日、2025年6月11日、2025年6月17日、2025年6月23日 及2025 年8月21日的公告（「該等公告」），內 容 有 關（其 中 包 括）其 股 份 回 購 計 劃。本 公 司 將 根 據 市 況 及 資 金 安 排，於 市 場 上 回 購 總 額 最 多1億 港 元 的 股 份。除 另 有 說 明 者 外，本 公 告 所 用 詞 彙 與 該 等 公 告 所 界 定 者 具 相 同 涵 義。 董 事 會 進 一 步 宣 佈，於2025年10月15日，本 公 司 根 據2025年股份回購授權回購 股 份。合 共100,000股 股 份 已 於 市 ...

Core Viewpoint - The company, Yaoshi Bang, has demonstrated strong growth in its business, particularly in its proprietary brand segment, which has become a key driver of the group's performance [1] Group 1: Business Performance - As of October 9, the company's stock rose over 3%, reaching HKD 12.12 with a trading volume of HKD 38.2278 million [1] - The total transaction value of the company's proprietary brand business for the third quarter of 2025 was approximately CNY 658.4 million, representing a year-on-year increase of 163% [1] - The transaction value of the company's proprietary brand business alone was approximately CNY 491.5 million, showing a significant year-on-year growth of 334.2% [1]

Core Insights - The core strategy of the company is to enhance profitability through the launch of its own brand products, which is a key component of its "upward move" plan [1] Business Strategy - The company is actively seeking deep collaborations with pharmaceutical companies to help them launch products tailored to downstream demand, aiming to convert potential market opportunities into tangible sales [1] - The company leverages its established brand influence and channel advantages to strategically expand its own brand product offerings, focusing on high-quality products that meet diverse market needs [1] Financial Performance - For the three months ending September 30, 2025, the total transaction value of the brand launch business, including the company's own brand business, reached 658 million yuan, representing a year-on-year increase of 163.0% [1]

格隆汇10月9日丨药师帮(09885.HK)公告，厂牌首推业务乃集团"向上走"方案中的一项重要战略，同时 作为高利润业务，因此对提升盈利能力而言举足轻重。公司自其他业务运营所获得的洞察，公司积极寻 求与药企建立深度合作，旨在协助它们将针对下游需求定制的产品推向更广阔的市场，从而将潜在的市 场机遇转化为实实在在的销售业绩。另一方面，依托公司已经构建的品牌影响力和渠道优势，其战略性 推进自有品牌产品的拓展，致力于推出品类丰富且紧密贴合市场需求的高质量自有品牌产品，以满足更 广泛下游用户的多元化需求。截至2025年9月30日止3个月，厂牌首推业务(包括集团自有品牌业务)交易 总额6.58亿元，同比增长163.0%。 ...

Core Viewpoint - The company reported significant growth in its business operations, particularly in its proprietary brand segment, indicating strong market performance and potential for future expansion [1] Group 1: Financial Performance - The total transaction volume for the company's flagship business, including its proprietary brand operations, reached approximately 658.4 million yuan in the third quarter of 2025, representing a year-on-year increase of 163% [1] - The transaction volume for the company's proprietary brand business was approximately 491.5 million yuan, showing a remarkable year-on-year growth of 334.2% [1]

Group 1 - The core viewpoint of the article highlights the significant growth in the transaction volume of the company's brand business, with a total transaction amount of approximately 658.4 million yuan in Q3 2025, representing a year-on-year increase of 163% [1] - The company's proprietary brand business achieved a transaction total of approximately 491.5 million yuan, showing a remarkable year-on-year growth of 334.2% [1]

本公告乃藥師幫股份有限公司（「本公司」）自 願 刊 發，以 告 知 其 股 東 及 潛 在 投 資 者有關本公司連同其附屬公司及綜合聯屬實體（「本集團」）若干業務發展最新 情 況。除 另 有 界 定 者 外，本 公 告 所 用 詞 彙 與 本 公 司 於2025年4月25日刊發的年度 報 告（「年 報」）所 界 定 者 具 相 同 涵 義。 茲提述本公司日期為2025年5月14日 有 關 業 務 發 展 最 新 情 況 的 自 願 性 公 告。廠 牌首推業務乃本集團「向 上 走」方 案 中 的 一 項 重 要 戰 略，同 時 作 為 高 利 潤 業 務， 因 此 對 提 升 盈 利 能 力 而 言 舉 足 輕 重。誠 如 年 報 所 披 露，根 據 本 公 司 自 其 他 業 務 運 營 所 獲 得 的 洞 察，本 公 司 積 極 尋 求 與 藥 企 建 立 深 度 合 作，旨 在 協 助 它 們 將 針 對 下 游 需 求 定 制 的 產 品 推 向 更 廣 闊 的 市 場，從 而 將 潛 在 的 市 場 機 遇 轉 化 為 實 實 在 在 的 銷 售 業 績。另 一 方 面，依 託 本 公 司 已 經 構 ...

Group 1 - The core viewpoint is that Yaoshi Bang (09885) has shown strong market performance, with its stock price rising to 12.4 HKD, marking a year-to-date increase of over 142% since September 25 [1] - The continuous rise in stock price is attributed to the gradual alleviation of early investor selling pressure, optimization of the company's equity structure, and strong performance fundamentals [1] - The exit of early financial investors has created space for long-term institutional investors, enhancing the stability and quality of the shareholder base [1] Group 2 - In the first half of 2025, the company achieved a revenue of 9.843 billion CNY, a year-on-year increase of 11.7%, and a net profit of 78.117 million CNY, a surge of 258% compared to the same period in 2024 [2] - The change in equity structure is seen as a positive factor, allowing the market to focus more on the company's long-term narrative [2] - The valuation of the company remains attractive relative to its growth potential and industry position, with significant room for value re-evaluation if high growth expectations are met [2]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 藥師幫股份有限公司 (於開曼群島註冊成立之有限公司) 呈交日期: 2025年10月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09885 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 20,000,000,000 | USD | 0.0000025 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 20,000,000,000 | USD | 0.0000025 | USD | | 50,000 | 本 ...

Group 1: Hong Kong Stocks - China Metallurgical Group (01618) rose nearly 7%, with institutions stating that the value of this resource-rich construction company needs urgent reassessment [1] - Rongchang Bio (09995) increased over 5%, as its innovative ophthalmic drug RC28 has been submitted for listing, following a partnership with Santen China [1] - Laikang Pharmaceutical-B (02105) surged nearly 6%, with a cumulative increase of 36% over the last three trading days, driven by positive preliminary results from the Phase I clinical MAD study of LAE102 [1] - UBTECH Robotics (09880) rose over 5%, with a report from CMB International recommending UBTECH as the top pick in the humanoid robot sector and raising its target price [1] - Innovent Biologics (09969) increased over 6%, as the company announced the first prescriptions for Tanshitumomab in several provinces [1] - BrainCo-B (06681) surged over 16%, benefiting from policy catalysts in the brain-computer interface industry, with its cognitive impairment digital therapy product having a first-mover advantage [1] - Yaoshi Bang (09885) rose over 10%, with high-margin business accelerating growth and POCT devices expected to see increased deployment in the second half of the year [1] - DCH Holdings (00179) fell over 7%, as Citigroup downgraded its investment rating from "Buy" to "Neutral," citing limited upside potential for the stock [1] - Minmetals Resources (01208) rose over 2%, planning to issue $500 million zero-coupon convertible bonds maturing in 2030 for overseas debt refinancing [1][2] Group 2: US Stocks - Alibaba (BABA.US) rose 4.65%, with Morgan Stanley reiterating an "Overweight" rating and raising the ADR target price from $165 to $200 [3] - Li Auto (LI.US) increased 3.57%, as the Li One officially commenced delivery at the Changzhou smart manufacturing base, with a report indicating that the i6 model's sales performance is expected to outperform the i8 [3] - JD.com (JD.US) rose 0.15%, announcing that the 2025 Double 11 shopping festival will start on October 9 at 8 PM, two days earlier than last year [3] - Xpeng Motors (XPEV.US) increased 1.76%, with the company announcing that the Xpeng MONA M03 has delivered a total of 180,000 units [3] - New Oriental (EDU.US) rose 4.38%, with a report indicating that the overall business development of the group is stabilizing [3] - Merus (MRUS.US) surged 35.97%, following an agreement with Danish biotech company Genmab for a cash acquisition at $97 per share [3] - Novo Nordisk (NVO.US) fell 0.20%, as Morgan Stanley downgraded its rating to "Sell" and reduced the target price from $99 to $47 [4] - MoonLake (MLTX.US) plummeted 89.93%, with trial results for its therapeutic drug falling far below expectations, leading to a significant target price cut by RBC [4] - TSMC (TSM.US) fell 0.05%, reaffirming that it has not engaged in discussions regarding potential investments or collaborations with any companies [4] - Micron Technology (MU.US) rose 4.22%, with Morgan Stanley predicting that the storage industry price increase cycle may continue into next year [4]